| pubmed-article:19704063 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:19704063 | lifeskim:mentions | umls-concept:C0023434 | lld:lifeskim |
| pubmed-article:19704063 | lifeskim:mentions | umls-concept:C0393022 | lld:lifeskim |
| pubmed-article:19704063 | lifeskim:mentions | umls-concept:C0010583 | lld:lifeskim |
| pubmed-article:19704063 | lifeskim:mentions | umls-concept:C0026259 | lld:lifeskim |
| pubmed-article:19704063 | lifeskim:mentions | umls-concept:C0205177 | lld:lifeskim |
| pubmed-article:19704063 | lifeskim:mentions | umls-concept:C0059985 | lld:lifeskim |
| pubmed-article:19704063 | lifeskim:mentions | umls-concept:C0040808 | lld:lifeskim |
| pubmed-article:19704063 | lifeskim:mentions | umls-concept:C0205250 | lld:lifeskim |
| pubmed-article:19704063 | pubmed:issue | 27 | lld:pubmed |
| pubmed-article:19704063 | pubmed:dateCreated | 2009-10-2 | lld:pubmed |
| pubmed-article:19704063 | pubmed:abstractText | The addition of monoclonal antibodies to chemotherapy has significantly improved treatment of chronic lymphocytic leukemia (CLL). Based on excellent results with the chemotherapy-only regimen fludarabine, cyclophosphamide, and mitoxantrone (FCM), we built a new chemoimmunotherapy combination--rituximab plus FCM (R-FCM). We report a phase II clinical trial consisting of an initial treatment with R-FCM followed by rituximab maintenance. | lld:pubmed |
| pubmed-article:19704063 | pubmed:language | eng | lld:pubmed |
| pubmed-article:19704063 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19704063 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:19704063 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19704063 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19704063 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19704063 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19704063 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19704063 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:19704063 | pubmed:month | Sep | lld:pubmed |
| pubmed-article:19704063 | pubmed:issn | 1527-7755 | lld:pubmed |
| pubmed-article:19704063 | pubmed:author | pubmed-author:BoschFrancesc... | lld:pubmed |
| pubmed-article:19704063 | pubmed:author | pubmed-author:MontserratEmi... | lld:pubmed |
| pubmed-article:19704063 | pubmed:author | pubmed-author:JarqueIsidroI | lld:pubmed |
| pubmed-article:19704063 | pubmed:author | pubmed-author:DelgadoJulioJ | lld:pubmed |
| pubmed-article:19704063 | pubmed:author | pubmed-author:VillamorNeusN | lld:pubmed |
| pubmed-article:19704063 | pubmed:author | pubmed-author:EscodaLourdes... | lld:pubmed |
| pubmed-article:19704063 | pubmed:author | pubmed-author:GonzálezYolan... | lld:pubmed |
| pubmed-article:19704063 | pubmed:author | pubmed-author:TerolMaría... | lld:pubmed |
| pubmed-article:19704063 | pubmed:author | pubmed-author:FerraChristel... | lld:pubmed |
| pubmed-article:19704063 | pubmed:author | pubmed-author:AbellaEugenia... | lld:pubmed |
| pubmed-article:19704063 | pubmed:author | pubmed-author:González-Barc... | lld:pubmed |
| pubmed-article:19704063 | pubmed:author | pubmed-author:EstanyCristin... | lld:pubmed |
| pubmed-article:19704063 | pubmed:author | pubmed-author:MuntañolaAnaA | lld:pubmed |
| pubmed-article:19704063 | pubmed:author | pubmed-author:CarbonellFéli... | lld:pubmed |
| pubmed-article:19704063 | pubmed:author | pubmed-author:SalameroOlgaO | lld:pubmed |
| pubmed-article:19704063 | pubmed:author | pubmed-author:AbrisquetaPau... | lld:pubmed |
| pubmed-article:19704063 | pubmed:author | pubmed-author:FerrerSecundi... | lld:pubmed |
| pubmed-article:19704063 | pubmed:author | pubmed-author:González... | lld:pubmed |
| pubmed-article:19704063 | pubmed:author | pubmed-author:García... | lld:pubmed |
| pubmed-article:19704063 | pubmed:author | pubmed-author:MonzóEncarnac... | lld:pubmed |
| pubmed-article:19704063 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:19704063 | pubmed:day | 20 | lld:pubmed |
| pubmed-article:19704063 | pubmed:volume | 27 | lld:pubmed |
| pubmed-article:19704063 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:19704063 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:19704063 | pubmed:pagination | 4578-84 | lld:pubmed |
| pubmed-article:19704063 | pubmed:dateRevised | 2010-11-18 | lld:pubmed |
| pubmed-article:19704063 | pubmed:meshHeading | pubmed-meshheading:19704063... | lld:pubmed |
| pubmed-article:19704063 | pubmed:meshHeading | pubmed-meshheading:19704063... | lld:pubmed |
| pubmed-article:19704063 | pubmed:meshHeading | pubmed-meshheading:19704063... | lld:pubmed |
| pubmed-article:19704063 | pubmed:meshHeading | pubmed-meshheading:19704063... | lld:pubmed |
| pubmed-article:19704063 | pubmed:meshHeading | pubmed-meshheading:19704063... | lld:pubmed |
| pubmed-article:19704063 | pubmed:meshHeading | pubmed-meshheading:19704063... | lld:pubmed |
| pubmed-article:19704063 | pubmed:meshHeading | pubmed-meshheading:19704063... | lld:pubmed |
| pubmed-article:19704063 | pubmed:meshHeading | pubmed-meshheading:19704063... | lld:pubmed |
| pubmed-article:19704063 | pubmed:meshHeading | pubmed-meshheading:19704063... | lld:pubmed |
| pubmed-article:19704063 | pubmed:meshHeading | pubmed-meshheading:19704063... | lld:pubmed |
| pubmed-article:19704063 | pubmed:meshHeading | pubmed-meshheading:19704063... | lld:pubmed |
| pubmed-article:19704063 | pubmed:meshHeading | pubmed-meshheading:19704063... | lld:pubmed |
| pubmed-article:19704063 | pubmed:meshHeading | pubmed-meshheading:19704063... | lld:pubmed |
| pubmed-article:19704063 | pubmed:year | 2009 | lld:pubmed |
| pubmed-article:19704063 | pubmed:articleTitle | Rituximab, fludarabine, cyclophosphamide, and mitoxantrone: a new, highly active chemoimmunotherapy regimen for chronic lymphocytic leukemia. | lld:pubmed |
| pubmed-article:19704063 | pubmed:affiliation | Department of Hematology, Hospital Clínic, Villarroel 170, 08036 Barcelona, Spain. fbosch@clinic.ub.es | lld:pubmed |
| pubmed-article:19704063 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:19704063 | pubmed:publicationType | Comparative Study | lld:pubmed |
| pubmed-article:19704063 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| pubmed-article:19704063 | pubmed:publicationType | Clinical Trial, Phase II | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:19704063 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:19704063 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:19704063 | lld:pubmed |
